I took part in bluebird bio's webinar today. I wanted to get their point of view of the recent negative press that has been directed at the gene therapy efforts. Personally, I feel that those making these negative reports have an agenda that includes attempting to lower the stock value, so they can buy it at a cheaper price. Following this webinar, I feel even more strongly about that.
Bluebird will begin trials on beta zero patients in a separate trial. They pointed out that it is still early in the trials and the results so far have been very good overall. They do expect to continue to learn which approaches work best with different genotypes. When I asked if they were optimistic about the future of their attempts with beta zero patients, without hesitation, the doctor stated that they are very optimistic. He mentioned that they continue to work on improving the vector used. We also need to understand that these are early trials and that things like the preparation and the dosing are variables that will become less variable once they have done more patients and see what is working best for different sets of patients. He also mentioned that in most of the beta zero patients already treated, there is a slow ongoing increase in the hemoglobin produced by the new gene.
I remain quite optimistic about the future of gene therapy. Today's vector is far superior to the original vector and there is reason to believe that further improvements will be made. And we must not forget that there are other efforts going on to cure thalassemia with gene therapy, and we know very little about the potential of these other efforts.